Research - Genzyme, a subsidiary of Sanofi (NYSE:SNY), announced Wednesday night that the FDA has approved Aubagio, its oral, once-daily treatment for Relapsing Remitting Multiple Sclerosis (RRMS). … Continue Reading
Read NowLong Ideas - Amarin Corp. (NASDAQ:AMRN) is under pressure for a second day on investor concerns related to the FDA pushing back a decision on NCE status for … Continue Reading
Read NowLong Ideas - Analysts and investors are refocusing on the opportunity for Pain Therapeutics’ (NASDAQ:PTIE) lead drug candidate, Remoxy. Remoxy is an extended-release formulation of the widely used … Continue Reading
Read NowResearch - BioSante Pharmaceuticals (NASDAQ:BPAX) is giving up gains from Tuesday’s momentary spike and is down 22%, from $1.66 to $1.35. The company reported completion of a … Continue Reading
Read NowResearch - On August 27th the FDA is set to decide on whether to approve Gilead Science’s (NASDA:GILD) pending HIV treatment, the Quad. If approved, the Quad … Continue Reading
Read NowLong Ideas - The Cooper Companies (NYSE:COO) became known as a “sleep at night” stock, with this leading contact lens provider beating estimates 8 quarters in a row. … Continue Reading
Read NowResearch - Short interest in ResMed Inc. (NYSE:RMD) is at its highest point this year, signaling that investors are growing increasingly bearish on the company’s valuation and … Continue Reading
Read Now